Brief: Unity Biotechnology Announces Improvement In Visual Acuity Sustained Through 24 Weeks Following Single Dose Of UBX1325 In Phase 1 Study

Unity Biotechnology

09/11/2021 12:33

Nov 9 (Reuters) - UNITY Biotechnology Inc  UBX.O :
    * UNITY BIOTECHNOLOGY ANNOUNCES IMPROVEMENT IN VISUAL ACUITY
SUSTAINED THROUGH 24 WEEKS FOLLOWING SINGLE DOSE OF UBX1325 IN
PHASE 1 STUDY OF PATIENTS WITH ADVANCED VASCULAR EYE DISEASE
    * UNITY BIOTECHNOLOGY INC - MAJORITY OF PATIENTS WITH DME
ACROSS
ALL DOSES HAD RAPID IMPROVEMENTS IN VISION
    * UNITY BIOTECHNOLOGY - PATIENTS IN HIGHER DOSE COHORTS
SHOWED
MEAN GAIN OF 9.5 ETDRS LETTERS IN BCVA AT 24 WEEKS AFTER  SINGLE
INJECTION OF UBX1325
    * UNITY BIOTECHNOLOGY INC - MAJORITY OF WET AMD PATIENTS
TREATED
WITH UBX1325 SHOWED RAPID GAINS IN VISUAL ACUITY
    * UNITY BIOTECHNOLOGY INC - PHASE 2 STUDY IN WET AMD IS
PLANNED
FOR FIRST HALF OF 2022, WITH 12-WEEK DATA EXPECTED IN SECOND
HALF OF YEAR

Source text for Eikon:  ID:nGNX2wHHSm 
Further company coverage:  UBX.O